Access

Why do new medicines reach patients faster in the United States?

HRSA finds 340B covered entity purchases have eclipsed $100 billion

Surge in out-of-pocket costs for commercially insured patients places heaviest burden on the most vulnerable

Who’s driving the surge in the 340B Program?

How do 340B growth drivers vary by hospital size and teaching status?

How do patients’ perspectives on retinitis pigmentosa differ from those of the general public?

Perspective matters: The importance of understanding lived experience in considering the value of treatment

Do expedited FDA approvals translate to faster insurance coverage?

“Insured but not covered”: Patient voices on insurance design

Insurance design shapes affordability and access for people with chronic disease